Propeller Health is partnering with Aptar Pharma for the development of technology based on metered dose inhaler systems (MDIs) for the treatment of asthma and COPD.
Under the terms of the partnership, Propeller and Aptar will work to develop the first integrated connected MDI, with an integrated sensor and a new electronic dose counter. The device, which is currently under licensing, is expected to enter clinical trials later in 2016.
Pressurized MDIs are inhaler devices that deliver aerosolized drugs including bronchodilators, corticosteroids, and combinations that are used every day by patients suffering with chronic respiratory diseases such as COPD or asthma. The new collaboration between Propeller and Aptar will develop the first connected inhaler, a major improvement in MDIs industry.
The new connected inhaler device will combine the MDI components developed by Aptar and the sensor technology developed by Propeller, which will allow for a reliable and accurate monitoring system of the patient’s use of inhaler drugs. Patients and providers will have all the information needed on how to use the cMDI.
Propeller creates a custom view of each patient, allowing them and their physicians to better understand the impact and management of their disease in daily life. The Propeller platform has been used by patients in more than 35 commercial programs across the US, including major healthcare systems, payers, employers, and other commercial partners.
